Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients
| Autor: | Tatsuya Yoshida, Yasushi Goto, Takaaki Mizuno, Yuji Matsumoto, Yusuke Okuma, Noboru Yamamoto, Noriko Motoi, Hitomi Jo, Yasushi Yatabe, Masayuki Shirasawa, Yukiko Shimoda, Yuichiro Ohe, Yuki Shinno, Hidehito Horinouchi |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Lung Neoplasms Time Factors non-small cell lung cancer (NSCLC) CD8-Positive T-Lymphocytes Risk Assessment B7-H1 Antigen Lymphocytes Tumor-Infiltrating Risk Factors Carcinoma Non-Small-Cell Lung Internal medicine Humans Medicine Lung cancer Immune Checkpoint Inhibitors Aged Retrospective Studies Aged 80 and over Smokers Predictive marker business.industry Tumor-infiltrating lymphocytes Smoking General Medicine Middle Aged medicine.disease Progression-Free Survival Blockade Nivolumab Female Non small cell business CD8 |
| Zdroj: | Anticancer Research. 41:5739-5747 |
| ISSN: | 1791-7530 0250-7005 |
| DOI: | 10.21873/anticanres.15390 |
| Popis: | BACKGROUND/AIM Programmed death-ligand 1 (PD-L1) expression on tumor cells is a predictive biomarker of programmed cell death 1 (PD-1) blockade therapy. This study sought to clarify predictors of the efficacy of nivolumab in non-small cell lung cancer (NSCLC) patients with PD-L1 expression-negative tumors. PATIENTS AND METHODS We retrospectively reviewed the records of advanced NSCLC patients between January 2016 and April 2019, and investigated the predictive marker of nivolumab including the status of CD8+ tumor infiltrating lymphocytes (TILs). RESULTS A total of 70 NSCLC patients were included. Overall response rate (ORR) and progression-free survival (PFS) were better in patients with a heavy smoking history (smoking index: SI≥600) than in those without (SI |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|